Blueprint Medicines Corp reports results for the quarter ended in December - Earnings Summary

Blueprint Medicines

16/02/2023 14:30

* Blueprint Medicines Corp  BPMC.OQ  reported a quarterly
adjusted
loss of $2.65​​ per share for the quarter ended in December. The
mean expectation of eighteen analysts for the quarter was for a
loss of $2.65 per share.
    * Revenue fell 63.8% to $38.78 million from a year ago;
analysts
expected $34.44 million. 
    * Blueprint Medicines Corp's reported EPS for the quarter
was a
loss of $2.65​.
    * The mean earnings estimate of analysts had risen by
about 0.2%
in the last three months.​ 
    * In the last 30 days three analysts negatively revised
earnings
estimates 
    * Blueprint Medicines Corp shares had risen by 0.5% this
quarter.
    * The company reported a quarterly loss of $158.64 million.
    * Wall Street's median 12-month price target for Blueprint
Medicines Corp is $75.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 6
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from Refinitiv data February
16 at 02:30 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -2.65          -2.65          Met
 Sep. 30 2022      -2.49          -2.23          Beat
 Jun. 30 2022      -2.23          -2.68          Missed
 Mar. 31 2022      -1.86          -1.79          Beat